

Xavier Mariette

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4428101/publications.pdf>

Version: 2024-02-01

389
papers

39,623
citations

3731

89
h-index

3323

184
g-index

404
all docs

404
docs citations

404
times ranked

32968
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Role of interaction between B cells and epithelial cells in pSS" by Pringle et al. Annals of the Rheumatic Diseases, 2022, 81, e261-e261.	0.9	0
2	Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology, 2022, 61, 953-962.	1.9	15
3	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2022, 81, 145-150.	0.9	30
4	Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. Lancet Rheumatology, The, 2022, 4, e8-e11.	3.9	29
5	Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Science Translational Medicine, 2022, 14, eabj7521.	12.4	71
6	CD4 ⁺ T-cell DNA methylation changes during pregnancy significantly correlate with disease-associated methylation changes in autoimmune diseases. Epigenetics, 2022, 17, 1040-1055.	2.7	4
7	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2022, 81, 34-40.	0.9	26
8	Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry. Joint Bone Spine, 2022, 89, 105310.	1.6	2
9	Safety and efficacy of subcutaneous ivalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet, The, 2022, 399, 161-171.	13.7	72
10	Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF. RMD Open, 2022, 8, e001697.	3.8	1
11	Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells. Frontiers in Immunology, 2022, 13, 808606.	4.8	7
12	Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases. Arthritis and Rheumatology, 2022, 74, 927-933.	5.6	52
13	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the Rheumatic Diseases, 2022, 81, 695-709.	0.9	130
14	Fish Consumption and Risk of Rheumatoid Arthritis: Findings from the E3N Cohort Study. Nutrients, 2022, 14, 861.	4.1	5
15	Anthropometric Measures and Risk of Rheumatoid Arthritis in the French E3N Cohort Study. Nutrients, 2022, 14, 934.	4.1	0
16	Restoration of Default Blood Monocyte-Derived Macrophage Polarization With Adalimumab But Not Etanercept in Rheumatoid Arthritis. Frontiers in Immunology, 2022, 13, 832117.	4.8	5
17	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.9	49
18	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Annals of the Rheumatic Diseases, 2022, 81, 1628-1639.	0.9	89

#	ARTICLE	IF	CITATIONS
19	Passive smoking in childhood and adulthood and risk of rheumatoid arthritis in women: results from the French E3N cohort study. <i>RMD Open</i> , 2022, 8, e001980.	3.8	5
20	Characteristics of Sjögren's syndrome associated with rheumatoid arthritis. <i>RMD Open</i> , 2022, 8, e002234.	3.8	6
21	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.8	12
22	Lifetime female hormonal exposure and risk of rheumatoid arthritis in postmenopausal women: Results from the French E3N cohort. <i>Joint Bone Spine</i> , 2022, 89, 105374.	1.6	3
23	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	1.9	12
24	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 979-989.	0.9	27
25	Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group. <i>EClinicalMedicine</i> , 2022, 46, 101362.	7.1	20
26	Features of non-Hodgkin's lymphoma diagnosed in minor salivary gland biopsies from primary Sjögren's syndrome patients. <i>Rheumatology</i> , 2022, 61, 3818-3823.	1.9	8
27	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
28	OA01 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Rheumatology</i> , 2022, 61, .	1.9	0
29	Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma. <i>Joint Bone Spine</i> , 2022, 89, 105390.	1.6	1
30	Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses. <i>RMD Open</i> , 2022, 8, e002308.	3.8	11
31	A Genetic Association Test Accounting for Skewed X-Inactivation With Application to Biotherapy Immunogenicity in Patients With Autoimmune Diseases. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	0
32	Variability of Primary Sjögren's Syndrome Is Driven by Interferon- γ and Interferon- α Blood Levels Are Associated With the Class II HLA-DQ Locus. <i>Arthritis and Rheumatology</i> , 2022, 74, 1991-2002.	5.6	15
33	Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. <i>RMD Open</i> , 2022, 8, e002139.	3.8	6
34	SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. <i>Rheumatology</i> , 2021, 60, 2946-2957.	1.9	15
35	Myositis as a manifestation of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e42-e42.	0.9	106
36	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 32.	5.1	654

#	ARTICLE	IF	CITATIONS
37	Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2021, 73, 631-640.	5.6	26
38	Risedronate-induced rhabdomyolysis in a patient with inflammatory myopathy. <i>Joint Bone Spine</i> , 2021, 88, 105090.	1.6	1
39	Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA). <i>Rheumatology</i> , 2021, 60, 888-895.	1.9	21
40	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. <i>Rheumatology</i> , 2021, 60, 1364-1375.	1.9	26
41	Mediterranean Diet and Risk of Rheumatoid Arthritis: Findings From the French E3N-EPIC Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 69-77.	5.6	30
42	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	8.0	35
43	18F-FDG PET/CT and MRI findings of Shulman syndrome also known as eosinophilic fasciitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2049-2050.	6.4	1
44	Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 803-815.	0.9	31
45	Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001549.	3.8	14
46	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.9	37
47	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021, 38, 265-284.	2.7	4
48	Female hormonal exposures and risk of rheumatoid arthritis in the French E3N-EPIC cohort study. <i>Rheumatology</i> , 2021, 60, 4790-4800.	1.9	16
49	TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1 ³ positive cancer-associated dermatomyositis. <i>Rheumatology</i> , 2021, 60, 5863-5867.	1.9	10
50	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 295-304.	10.7	232
51	Association between T follicular helper cells and T peripheral helper cells with B-cell biomarkers and disease activity in primary Sjögren syndrome. <i>RMD Open</i> , 2021, 7, e001442.	3.8	12
52	Systemic and organ-specific immune-related manifestations of COVID-19. <i>Nature Reviews Rheumatology</i> , 2021, 17, 315-332.	8.0	194
53	Tocilizumab in Treatment for Patients With COVID-19—Reply. <i>JAMA Internal Medicine</i> , 2021, 181, 1020-1021.	5.1	1
54	Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice. <i>Clinical and Experimental Immunology</i> , 2021, 205, 169-181.	2.6	0

#	ARTICLE	IF	CITATIONS
55	Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine. <i>Rheumatology International</i> , 2021, 41, 1593-1600.	3.0	13
56	Current and future therapies for primary Sjögren syndrome. <i>Nature Reviews Rheumatology</i> , 2021, 17, 475-486.	8.0	64
57	Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS). <i>Joint Bone Spine</i> , 2021, 88, 105162.	1.6	12
58	Differential levels of IFN γ subtypes in autoimmunity and viral infection. <i>Cytokine</i> , 2021, 144, 155533.	3.2	12
59	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. <i>European Journal of Cancer</i> , 2021, 158, 208-216.	2.8	33
60	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	7.4	498
61	Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1241.	5.1	111
62	Phenotypic switch from non-active primary Sjögren's syndrome to severe systemic Lupus erythematosus after COVID-19 infection in an elderly man. <i>Joint Bone Spine</i> , 2021, 88, 105228.	1.6	2
63	Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001472.	3.8	10
64	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 329-338.	0.9	61
65	Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls. <i>Journal of Hematology and Oncology</i> , 2021, 14, 166.	17.0	24
66	Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001899.	3.8	8
67	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. <i>RMD Open</i> , 2021, 7, .	3.8	0
68	Flare of a mixed cryoglobulinaemic vasculitis after obinutuzumab infusion. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 52-55.	0.8	1
69	Flare of a mixed cryoglobulinaemic vasculitis after obinutuzumab infusion. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 52-55.	0.8	3
70	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. <i>RMD Open</i> , 2021, 7, e001698.	3.8	13
71	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.8	12
72	Concomitant fibromyalgia in primary Sjögren's syndrome in the French ASSESS cohort: comparison of the ACR 1990 and ACR 2016 criteria, FIRST questionnaire and physician's opinion. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 140-145.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Concomitant fibromyalgia in primary Sjögren's syndrome in the French ASSESS cohort: comparison of the ACR 1990 and ACR 2016 criteria, FIRST questionnaire and physician's opinion.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 140-145.	0.8	0
74	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.8	0
75	Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial. Rheumatology, 2020, 59, 107-111.	1.9	50
76	Alcohol is not the missing link between <i>Porphyromonas gingivalis</i> -related periodontitis and radiological progression in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, e107-e107.	0.9	2
77	Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. Rheumatology, 2020, 59, 1347-1354.	1.9	28
78	Role of good oral hygiene on clinical evolution of rheumatoid arthritis: a randomized study nested in the ESPOIR cohort. Rheumatology, 2020, 59, 988-996.	1.9	20
79	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Annals of the Rheumatic Diseases, 2020, 79, 3-18.	0.9	307
80	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Annals of the Rheumatic Diseases, 2020, 79, 88-93.	0.9	63
81	JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis. Cellular and Molecular Immunology, 2020, 17, 552-553.	10.5	15
82	Low Influenza, Pneumococcal and Diphtheria-Tetanus-Poliomyelitis Vaccine Coverage in Patients with Primary Sjögren's Syndrome: A Cross-Sectional Study. Vaccines, 2020, 8, 3.	4.4	9
83	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. Rheumatology, 2020, 59, 2350-2359.	1.9	54
84	Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Annals of the Rheumatic Diseases, 2020, 79, 1532-1543.	0.9	23
85	To immunosuppress: whom, when and how? That is the question with COVID-19. Annals of the Rheumatic Diseases, 2020, 79, 1129-1131.	0.9	16
86	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.9	35
87	Salivary gland epithelial cells from patients with Sjögren's syndrome induce B-lymphocyte survival and activation. Annals of the Rheumatic Diseases, 2020, 79, 1468-1477.	0.9	62
88	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open, 2020, 6, e001395.	3.8	100
89	Chronic diarrhoea and risk of rheumatoid arthritis: findings from the French E3N-EPIC Cohort Study. Rheumatology, 2020, 59, 3767-3775.	1.9	16
90	Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 2020, 6, 38.	30.5	684

#	ARTICLE	IF	CITATIONS
91	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.9	204
92	Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 701-708.	3.4	11
93	Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 309-311.	0.9	10
94	Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach. <i>BMC Medical Research Methodology</i> , 2020, 20, 69.	3.1	1
95	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020, 130, 39-50.	2.8	37
96	Seasonal effect on fatigue, pain and dryness in primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2020, 22, 39.	3.5	8
97	Small fiber neuropathy in Sjögren syndrome: Comparison with other small fiber neuropathies. <i>Muscle and Nerve</i> , 2020, 61, 515-520.	2.2	14
98	Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. <i>Rheumatology</i> , 2020, 59, 3275-3283.	1.9	10
99	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
100	A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort. <i>Frontiers in Immunology</i> , 2020, 11, 608.	4.8	1
101	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	8.4	31
102	Autoimmune congenital heart block and primary Sjögren's syndrome: characterisation and outcomes of 49 cases. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 95-102.	0.8	2
103	Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e67-e67.	0.9	40
104	Passive smoking in childhood increases the risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1154-1162.	1.9	39
105	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
106	Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. <i>RMD Open</i> , 2019, 5, e000942.	3.8	45
107	Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients. <i>RMD Open</i> , 2019, 5, e000914.	3.8	7
108	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019, 5, e001064.	3.8	53

#	ARTICLE	IF	CITATIONS
109	Characterization of Phenotypes and Functional Activities of Leukocytes From Rheumatoid Arthritis Patients by Mass Cytometry. <i>Frontiers in Immunology</i> , 2019, 10, 2384.	4.8	9
110	Monocyte/Macrophage Abnormalities Specific to Rheumatoid Arthritis Are Linked to miR-155 and Are Differentially Modulated by Different TNF Inhibitors. <i>Journal of Immunology</i> , 2019, 203, 1766-1775.	0.8	49
111	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e85-e94.	3.9	76
112	Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2019, 364, l67.	2.3	76
113	Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 1153.	4.8	19
114	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and <i>CD39</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.9	25
115	Valine 11 and phenylalanine 13 have a greater impact on the T-cell response to citrullinated peptides than the 70-74 shared epitope of the DRB1 molecule in macaques. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 917-921.	0.9	6
116	Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma. <i>Rheumatology</i> , 2019, , .	1.9	56
117	Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients. <i>Rheumatology</i> , 2019, 58, 1498-1499.	1.9	7
118	Comment on: Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease? Reply. <i>Rheumatology</i> , 2019, 58, 1312-1313.	1.9	2
119	Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. <i>Clinical Rheumatology</i> , 2019, 38, 1413-1424.	2.2	21
120	SAT0179...CHANGE IN IMMUNOLOGICAL PARAMETERS DURING FOLLOW-UP OF PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME: DATA FROM THE FRENCH ASSESS COHORT. , 2019, , .		0
121	AB0462...IMMUNIZATION TO RITUXIMAB IS MORE FREQUENT IN AUTOIMMUNE SYSTEMIC AUTOIMMUNE DISEASES THAN IN RHEUMATOID ARTHRITIS AND MAY BE MANAGED BY SWITCHING FROM RITUXIMAB TO OFATUMUMAB. , 2019, , .		0
122	SAT0324...ARTICULAR MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB. , 2019, , .		1
123	FRI0607...IDENTIFICATION OF UNMET NEEDS RELATED TO RARE AND COMPLEX CONNECTIVE TISSUE AND MUSCULOSKELETAL DISEASES (RCTDS) ACROSS EU: THE EXPERIENCE OF THE ERN RECONNET. , 2019, , .		0
124	Improving accuracy of self-reported diagnoses of rheumatoid arthritis in the French prospective E3N-EPIC cohort: a validation study. <i>BMJ Open</i> , 2019, 9, e033536.	1.9	17
125	SP0190...2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJÖGREN'S SYNDROME WITH TOPICAL AND SYSTEMIC THERAPIES. , 2019, , .		3
126	Anti-RNP positivity in primary Sjögren's syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement. <i>RMD Open</i> , 2019, 5, e001033.	3.8	25

#	ARTICLE	IF	CITATIONS
127	Large granular lymphocyte expansions in primary Sjögren's syndrome: characteristics and outcomes. <i>RMD Open</i> , 2019, 5, e001044.	3.8	2
128	Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. <i>Rheumatology</i> , 2019, 58, vii49-vii58.	1.9	24
129	Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2019, 18, 9-14.	5.8	32
130	Usefulness of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Lymphoma in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2019, 71, 1147-1157.	5.6	30
131	Update of French society for rheumatology recommendations for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2019, 86, 135-150.	1.6	90
132	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2019, 71, 599-611.	5.6	142
133	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 967-975.	3.4	46
134	Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 282-284.	0.9	15
135	Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e46-e46.	0.9	31
136	Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS). <i>British Journal of Haematology</i> , 2019, 184, 472-475.	2.5	12
137	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.9	36
138	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 97-106.	0.8	6
139	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 114-122.	0.8	19
140	Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. <i>Rheumatology</i> , 2018, 57, 134-139.	1.9	21
141	Cost-effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before TNF-blockers therapy. <i>Presse Medicale</i> , 2018, 47, e9-e13.	1.9	2
142	Primary Sjögren's Syndrome. <i>New England Journal of Medicine</i> , 2018, 378, 931-939.	27.0	536
143	Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. <i>Rheumatology</i> , 2018, 57, 538-547.	1.9	43
144	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 763-773.	5.6	49

#	ARTICLE	IF	CITATIONS
145	B cells in the pathogenesis of primary Sjögren syndrome. <i>Nature Reviews Rheumatology</i> , 2018, 14, 133-145.	8.0	216
146	Iron Supplementation-Induced Phosphaturic Osteomalacia: FGF23 is the Culprit. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 540-542.	2.8	22
147	Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 468-470.	0.9	56
148	A multi-parameter response prediction model for rituximab in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2018, 85, 219-226.	1.6	22
149	Role of the IL-12/IL-35 balance in patients with Sjögren syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 258-268.e5.	2.9	34
150	TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. <i>Oncology</i> , 2018, 7, e1386826.	4.6	26
151	Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program. <i>Arthritis Care and Research</i> , 2018, 70, 685-694.	3.4	29
152	Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 133-140.	0.9	84
153	The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 162-164.	0.9	39
154	Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 228-233.	0.9	279
155	Low Percentage of Signal Regulatory Protein 1 α /2 α Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2018, 9, 2865.	4.8	9
156	Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1463-1470.	0.9	25
157	Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. <i>European Journal of Internal Medicine</i> , 2018, 57, 96-104.	2.2	29
158	Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1835-1836.	0.9	7
159	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 102-112.	0.8	37
160	A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. <i>Rheumatology</i> , 2017, 56, kew376.	1.9	38
161	Comparison of modified disease-activity scores with original composite scores for prediction of structural damages in rheumatoid arthritis: Data from the ESPOIR cohort. <i>Joint Bone Spine</i> , 2017, 84, 111-112.	1.6	0
162	Immunogenicity of tocilizumab in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 39-45.	1.6	32

#	ARTICLE	IF	CITATIONS
163	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. <i>Rheumatology</i> , 2017, 56, kew476.	1.9	10
164	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
165	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1161-1168.	0.9	200
166	Cost-effectiveness of rituximab strategies in rheumatoid arthritis. <i>Lancet, The</i> , 2017, 389, 365-366.	13.7	4
167	2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 9-16.	0.9	959
168	Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas. <i>Journal of Autoimmunity</i> , 2017, 80, 56-64.	6.5	34
169	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 386-391.	0.9	150
170	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1253-1262.	0.9	316
171	Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study. <i>RMD Open</i> , 2017, 3, e000345.	3.8	35
172	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
173	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1042-1050.	0.9	132
174	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
175	Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases. <i>Journal of Rheumatology</i> , 2017, 44, 1011-1017.	2.0	15
176	Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1747-1750.	0.9	200
177	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. <i>Journal of Autoimmunity</i> , 2017, 80, 10-27.	6.5	114
178	A new MHC-linked susceptibility locus for primary Sjögren's syndrome: MICA. <i>Human Molecular Genetics</i> , 2017, 26, 2565-2576.	2.9	22
179	Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial. <i>Value in Health</i> , 2017, 20, 577-585.	0.3	19
180	The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. <i>Joint Bone Spine</i> , 2017, 84, 571-576.	1.6	19

#	ARTICLE	IF	CITATIONS
181	Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trial. <i>Joint Bone Spine</i> , 2017, 84, 577-581.	1.6	10
182	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the European-European registry collaboration for abatacept (PANABA). <i>Clinical Rheumatology</i> , 2017, 36, 773-779.	2.2	33
183	Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000448.	3.8	16
184	Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid Arthritis Study) randomised controlled trial. <i>RMD Open</i> , 2017, 3, e000474.	3.8	13
185	Guidelines for treatment of primary Sjögren's syndrome: a first useful stone but still much to do. <i>Rheumatology</i> , 2017, 56, 1641-1642.	1.9	4
186	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2025-2030.	0.9	77
187	Association of the Presence of Anti-Carbamylated Protein Antibodies in Early Arthritis With a Poorer Clinical and Radiologic Outcome. <i>Arthritis and Rheumatology</i> , 2017, 69, 2292-2302.	5.6	48
188	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 2187-2192.	5.6	35
189	Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. <i>European Journal of Cancer</i> , 2017, 82, 34-44.	2.8	146
190	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1937-1948.	5.6	32
191	Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 735-741.	5.6	8
192	Malignancy and the Risks of Biologic Therapies. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 43-64.	1.9	22
193	Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial. <i>Arthritis Care and Research</i> , 2017, 69, 528-535.	3.4	65
194	Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ORA registry. <i>RMD Open</i> , 2017, 3, e000515.	3.8	14
195	Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. <i>RMD Open</i> , 2017, 3, e000538.	3.8	18
196	Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors. <i>Frontiers in Immunology</i> , 2017, 8, 500.	4.8	69
197	Both Systemic and Intra-articular Immunization with Citrullinated Peptides Are Needed to Induce Arthritis in the Macaque. <i>Frontiers in Immunology</i> , 2017, 8, 1816.	4.8	7
198	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. <i>PLoS Genetics</i> , 2017, 13, e1006820.	3.5	60

#	ARTICLE	IF	CITATIONS
199	Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1245-1250.	5.6	39
200	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1290-1300.	5.6	114
201	Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000205.	3.8	15
202	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	2.7	51
203	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1945-1950.	0.9	57
204	Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 294.	3.5	27
205	Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort. <i>RMD Open</i> , 2016, 2, e000179.	3.8	88
206	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.9	258
207	Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1809-1821.e12.	2.9	129
208	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. <i>Clinical Immunology</i> , 2016, 168, 25-29.	3.2	68
209	Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis. <i>Joint Bone Spine</i> , 2016, 83, 595-597.	1.6	4
210	Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1172.	7.4	160
211	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	12.8	73
212	Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-two Patients. <i>Arthritis and Rheumatology</i> , 2016, 68, 702-712.	5.6	57
213	Use of Biologics in Sjögren's Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 407-417.	1.9	23
214	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225
215	Paradoxical anti-TNF-associated TB worsening: Frequency and factors associated with IRIS. <i>Joint Bone Spine</i> , 2016, 83, 173-178.	1.6	28
216	Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjögren syndrome: comparison of different kits. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 633-635.	0.9	19

#	ARTICLE	IF	CITATIONS
217	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 137-156.	3.0	118
218	Renal involvement in primary Sjögren syndrome. <i>Nature Reviews Nephrology</i> , 2016, 12, 82-93.	9.6	160
219	Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 780-783.	0.9	40
220	Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 933-940.	0.9	77
221	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1213-1224.	6.1	44
222	Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid Arthritis Study). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 59-67.	0.9	119
223	New biological therapies in Sjögren's syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 783-793.	3.3	7
224	Association of Anti- <i>Porphyromonas gingivalis</i> Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1729-1737.	5.6	61
225	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?. <i>PLoS ONE</i> , 2015, 10, e0133907.	2.5	19
226	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	3.8	229
227	Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study. <i>Arthritis Research and Therapy</i> , 2015, 17, 241.	3.5	40
228	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. <i>RMD Open</i> , 2015, 1, e000128.	3.8	17
229	Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. <i>Rheumatology</i> , 2015, 54, 1699-1708.	1.9	49
230	Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , 2015, 54, 2230-2238.	1.9	220
231	Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 680-685.	5.8	58
232	Genetic contribution of DKK-1 polymorphisms to RA structural severity and DKK-1 level of expression. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1480-1481.	0.9	18
233	Orbital Myositis and Primary Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2015, 42, 1536-1537.	2.0	7
234	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1725-1733.	0.9	130

#	ARTICLE	IF	CITATIONS
235	Non HCV-related infectious cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey and systematic review of the literature. <i>Journal of Autoimmunity</i> , 2015, 65, 74-81.	6.5	76
236	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. <i>International Journal of Epidemiology</i> , 2015, 44, 1706-1721.	1.9	53
237	Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients. <i>Joint Bone Spine</i> , 2015, 82, 451-454.	1.6	9
238	Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. <i>British Journal of Haematology</i> , 2015, 168, 317-327.	2.5	225
239	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193
240	The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. <i>Human Molecular Genetics</i> , 2015, 24, 582-596.	2.9	74
241	Evaluation of Serum Interleukin-6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 905-912.	3.4	55
242	Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 526-531.	0.9	248
243	TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits. <i>PLoS ONE</i> , 2015, 10, e0122271.	2.5	120
244	Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort. <i>PLoS ONE</i> , 2015, 10, e0134974.	2.5	26
245	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. <i>PLoS ONE</i> , 2014, 9, e87645.	2.5	34
246	Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e113465.	2.5	41
247	Efficacy and Safety of Rituximab in Elderly Patients With Rheumatoid Arthritis Enrolled in a French Society of Rheumatology Registry. <i>Arthritis Care and Research</i> , 2014, 66, 1289-1295.	3.4	37
248	Usefulness of ¹⁸ F-fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Staging and Evaluation of Treatment Response in IgG4-Related Disease: A Retrospective Multicenter Study. <i>Arthritis Care and Research</i> , 2014, 66, 86-96.	3.4	158
249	Epidemiology of Primary Sjögren's Syndrome in a French Multiracial/Multiethnic Area. <i>Arthritis Care and Research</i> , 2014, 66, 454-463.	3.4	107
250	Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 249.	7.4	241
251	Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. <i>Joint Bone Spine</i> , 2014, 81, 352-359.	1.6	39
252	Outcome measures for primary Sjögren's syndrome: A comprehensive review. <i>Journal of Autoimmunity</i> , 2014, 51, 51-56.	6.5	77

#	ARTICLE	IF	CITATIONS
253	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
254	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	27.8	1,974
255	Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey. <i>Autoimmunity Reviews</i> , 2014, 13, 630-634.	5.8	23
256	Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1508-1514.	0.9	76
257	Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 287-297.	1.6	115
258	Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Française)</i> , 2014, 81, 303-312.	0.0	10
259	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.9	1,688
260	Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2074-2081.	0.9	204
261	Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2014, 51, 57-66.	6.5	123
262	Use of Whole-Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open-Label Trial. <i>Arthritis and Rheumatology</i> , 2014, 66, 2015-2025.	5.6	54
263	Treatment of Primary Sjögren Syndrome With Rituximab. <i>Annals of Internal Medicine</i> , 2014, 160, 233-242.	3.9	325
264	Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort. <i>PLoS ONE</i> , 2014, 9, e97077.	2.5	19
265	Advances in understanding the pathogenesis of primary Sjögren's syndrome. <i>Nature Reviews Rheumatology</i> , 2013, 9, 544-556.	8.0	288
266	Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. <i>Nature Genetics</i> , 2013, 45, 1284-1292.	21.4	427
267	Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1375-1381.	0.9	94
268	Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 165-178.	0.9	315
269	Downregulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon β mimetic. <i>Arthritis and Rheumatism</i> , 2013, 65, 447-456.	6.7	155
270	CCL19, a B Cell Chemokine, Is Related to the Decrease of Blood Memory B Cells and Predicts the Clinical Response to Rituximab in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2253-2261.	6.7	51

#	ARTICLE	IF	CITATIONS
271	Bacteremia in patients receiving TNF-alpha antagonists – A prospective multicenter study. <i>Journal of Infection</i> , 2013, 67, 524-528.	3.3	7
272	The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 665-671.	0.9	110
273	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	3.5	146
274	Role of Fms-like Tyrosine Kinase 3 Ligand as a Potential Biologic Marker of Lymphoma in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatism</i> , 2013, 65, 3218-3227.	6.7	46
275	NCR3/NKp30 Contributes to Pathogenesis in Primary Sjögren's Syndrome. <i>Science Translational Medicine</i> , 2013, 5, 195ra96.	12.4	99
276	Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 374-380.	0.9	59
277	Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1026-1031.	0.9	193
278	Potential Classification Criteria for Rheumatoid Arthritis After Two Years: Results From a French Multicenter Cohort. <i>Arthritis Care and Research</i> , 2013, 65, 1227-1234.	3.4	16
279	First-Year Radiographic Progression as a Predictor of Further Progression in Early Arthritis: Results of a Large National French Cohort. <i>Arthritis Care and Research</i> , 2013, 65, 1907-1915.	3.4	33
280	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013, 45, 468-469.	21.4	24
281	Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2013, 40, 1650-1657.	2.0	38
282	Incidence and Risk Factors of Legionella pneumophila Pneumonia During Anti-Tumor Necrosis Factor Therapy. <i>Chest</i> , 2013, 144, 990-998.	0.8	75
283	Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren's Syndrome. Data at Enrollment in the Prospective ASSESS Cohort. <i>PLoS ONE</i> , 2013, 8, e59868.	2.5	147
284	Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, e2-e2.	0.9	23
285	Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry). <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1429-1431.	0.9	24
286	Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1783-1790.	0.9	81
287	Primary Sjögren's Syndrome: Time for Prospective Cohorts. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 2022-2025.	1.6	4
288	Methylation profile of the promoter region of IRF5 in primary Sjögren's syndrome. <i>European Cytokine Network</i> , 2012, 23, 166-172.	2.0	25

#	ARTICLE	IF	CITATIONS
289	Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. <i>Blood</i> , 2012, 119, 5996-6004.	1.4	175
290	Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1243-1248.	0.9	74
291	Outcome measures for primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2012, 39, 97-102.	6.5	46
292	Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: Results from a French Multicenter Cohort. <i>Arthritis Care and Research</i> , 2012, 64, 872-880.	3.4	20
293	Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1895-1904.	0.9	345
294	EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 968-972.	0.9	383
295	Functional study of TNF- α promoter polymorphisms : literature review and meta-analysis. <i>European Cytokine Network</i> , 2011, 22, 88-102.	2.0	68
296	Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: A national multicentric retrospective study. <i>Arthritis Care and Research</i> , 2011, 63, 1339-1344.	3.4	61
297	B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study. <i>Arthritis and Rheumatism</i> , 2011, 63, 933-938.	6.7	129
298	Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3692-3701.	6.7	81
299	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.9	394
300	Induction of B Cell-Activating Factor by Viral Infection Is a General Phenomenon, but the Types of Viruses and Mechanisms Depend on Cell Type. <i>Journal of Innate Immunity</i> , 2011, 3, 200-207.	3.8	33
301	Cytomegalovirus Colitis and Hypo-IgG After Rituximab Therapy for Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 965-966.	2.0	22
302	Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. <i>Rheumatology</i> , 2011, 50, 222-229.	1.9	159
303	Pathogenesis of Sjögren's syndrome and therapeutic consequences. <i>Current Opinion in Rheumatology</i> , 2010, 22, 471-477.	4.3	78
304	Lymphoma, rheumatoid arthritis, and TNF- α antagonists. <i>Joint Bone Spine</i> , 2010, 77, 195-197.	1.6	13
305	Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. <i>Arthritis Care and Research</i> , 2010, 62, 551-558.	3.4	66
306	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2458-2466.	6.7	352

#	ARTICLE	IF	CITATIONS
307	Tumour necrosis factor γ 308A polymorphism is not associated with response to TNF α blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1022-1028.	0.9	81
308	Rheumatoid Arthritis of the Hand: Monitoring with a Simplified MR Imaging Scoring Method—Preliminary Assessment. <i>Radiology</i> , 2010, 256, 863-869.	7.3	23
309	EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1103-1109.	0.9	734
310	RANK and RANKL expression in giant-cell tumour of bone. <i>Lancet Oncology</i> , The, 2010, 11, 514.	10.7	18
311	IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3540-3542.	0.7	22
312	Exposition to anti-TNF drugs during pregnancy: Outcome of 15 cases and review of the literature. <i>Joint Bone Spine</i> , 2009, 76, 28-34.	1.6	109
313	B cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation. <i>European Journal of Immunology</i> , 2009, 39, 1271-1279.	2.9	35
314	Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates. <i>Journal of Clinical Oncology</i> , 2009, 27, 1564-1571.	1.6	491
315	Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type I IFN-dependent and -independent pathways. <i>European Journal of Immunology</i> , 2008, 38, 1058-1064.	2.9	141
316	Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. <i>Arthritis and Rheumatism</i> , 2008, 58, 88-97.	6.7	126
317	Le rituximab: une nouvelle possibilité thérapeutique dans la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Française)</i> , 2008, 75, 782-789.	0.0	3
318	Rituximab: A new therapeutic alternative in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2008, 75, 526-532.	1.6	30
319	Therapeutic Potential for B-Cell Modulation in Sjögren's Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2008, 34, 1025-1033.	1.9	19
320	Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 732-739.	0.9	175
321	Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 700-702.	0.9	159
322	Tumour necrosis factor receptor 2 (TNFRSF1B) association study in Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1684-1685.	0.9	5
323	Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 351-357.	0.9	261
324	Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1610-1615.	0.9	80

#	ARTICLE	IF	CITATIONS
325	Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 790-797.	0.9	77
326	Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. <i>Haematologica</i> , 2007, 92, e20-e23.	3.5	67
327	Potential of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. <i>Joint Bone Spine</i> , 2007, 74, 446-452.	1.6	18
328	Imaging for the diagnosis and follow-up of ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2007, 74, 338-345.	1.6	16
329	Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2007, 74, 330-337.	1.6	18
330	Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2007, 74, 346-352.	1.6	16
331	The ESPOIR cohort: A ten-year follow-up of early arthritis in France. <i>Joint Bone Spine</i> , 2007, 74, 440-445.	1.6	161
332	Recommendations of the French Society for Rheumatology regarding TNF \pm antagonist therapy in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2007, 74, 627-637.	1.6	70
333	Recommendations of the French Society for Rheumatology regarding TNF \pm antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. <i>Joint Bone Spine</i> , 2007, 74, 638-646.	1.6	98
334	Perioperative Management of Patients with Rheumatoid Arthritis Treated with TNF- \hat{I} Blocking Agents. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 202-203.	3.4	4
335	Small hepatic vein involvement in IgG multiple myeloma: a very unusual pattern of liver infiltration. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 127-129.	2.8	4
336	Anticentromere antibodies identify patients with Sjogren's syndrome and autoimmune overlap syndrome. <i>Journal of Rheumatology</i> , 2007, 34, 2253-8.	2.0	40
337	Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus. <i>Cytokine</i> , 2006, 33, 337-345.	3.2	15
338	Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006, 73, 388-395.	1.6	126
339	Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006, 73, 396-402.	1.6	58
340	Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006, 73, 379-387.	1.6	75
341	TNF \pm antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. <i>Joint Bone Spine</i> , 2006, 73, 547-553.	1.6	31
342	Recommendations of the French Society for Rheumatology. TNF \pm antagonist therapy in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2006, 73, 433-441.	1.6	49

#	ARTICLE	IF	CITATIONS
343	Failure to confirm coxsackievirus infection in primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2006, 54, 2026-2028.	6.7	26
344	Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2770-2775.	7.1	542
345	A Randomized Comparison of Dexamethasone + Thalidomide (Dex/Thal) vs Dex + Placebo (Dex/P) in Patients (pts) with Relapsing Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 3563-3563.	1.4	18
346	Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. <i>Journal of Rheumatology</i> , 2006, 33, 865-9.	2.0	22
347	Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. <i>European Cytokine Network</i> , 2006, 17, 290-3.	2.0	23
348	Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?. <i>Blood</i> , 2005, 105, 74-76.	1.4	200
349	Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005, 72, 163-170.	1.6	37
350	Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005, 72, 222-228.	1.6	43
351	Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005, 72, 229-234.	1.6	32
352	The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnF± therapy. <i>Joint Bone Spine</i> , 2005, 72, 456-460.	1.6	60
353	Mucosa-associated lymphoid tissue lymphoma of the thymus: a case report with no evidence of MALT1 rearrangement. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 189-193.	2.8	28
354	High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe. <i>Journal of Clinical Oncology</i> , 2005, 23, 9227-9233.	1.6	356
355	CD4 CD25 regulatory T cells are not impaired in patients with primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2005, 24, 235-242.	6.5	132
356	Retroperitoneal fibrosis secondary to spondylodiscitis after infection with <i>Prevotella</i> . <i>Journal of Rheumatology</i> , 2005, 32, 957-8.	2.0	4
357	Specific cardiomyopathy in lupus patients: report of three cases. <i>Joint Bone Spine</i> , 2004, 71, 66-69.	1.6	19
358	The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases. <i>Joint Bone Spine</i> , 2004, 71, 357-360.	1.6	6
359	Emerging biological therapies in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2004, 71, 470-474.	1.6	12
360	Place et forme de l'information et de l'éducation dans la prise en charge de personnes souffrant de polyarthrite rhumatoïde. Établissement de recommandations pour la pratique clinique à partir de données de la littérature et d'opinions d'experts (rencontres d'experts en rhumatologie). <i>Revue Du Rhumatisme (Edition Française)</i> , 2004, 71, S146-S155.	0.0	10

#	ARTICLE	IF	CITATIONS
361	Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS). <i>Arthritis and Rheumatism</i> , 2004, 50, 1270-1276.	6.7	368
362	Biothérapies émergentes dans la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2004, 71, 848-853.	0.0	3
363	The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Tj ETQq1 1 0,784314 rgBT /Over	1.3	46
364	Treatment of multiple myeloma. <i>Joint Bone Spine</i> , 2003, 70, 175-186.	1.6	10
365	Hepatitis C virus, arthritides, and arthromyalgia. <i>Joint Bone Spine</i> , 2003, 70, 246-247.	1.6	5
366	RANK (Receptor Activator of Nuclear Factor kappa B) and RANK Ligand Are Expressed in Giant Cell Tumors of Bone. <i>American Journal of Clinical Pathology</i> , 2002, 117, 210-216.	0.7	158
367	Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. <i>Blood</i> , 2002, 99, 3909-3915.	1.4	399
368	Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2002, 347, 89-94.	27.0	760
369	Current and potential treatments for primary Sjögren's syndrome. <i>Joint Bone Spine</i> , 2002, 69, 363-366.	1.6	19
370	Inhibiteurs du TNF-alpha en 2002: effets indésirables, surveillance, nouvelles indications en dehors de la polyarthrite rhumatoïde et des spondylarthropathies. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2002, 69, 982-991.	0.0	3
371	RANK (receptor activator of nuclear factor- κ B) and RANKL expression in multiple myeloma. <i>British Journal of Haematology</i> , 2002, 117, 86-92.	2.5	111
372	Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide. <i>Journal of Rheumatology</i> , 2002, 29, 1806-7.	2.0	14
373	Granulocyte colony-stimulating factor therapy resulting in a flare of systemic lupus erythematosus: comment on the article by Yang and Hamilton. <i>Arthritis and Rheumatism</i> , 2001, 44, 2458-2459.	6.7	14
374	Lymphomas in Patients with Sjögren's Syndrome: Review of the Literature and Physiopathologic Hypothesis. <i>Leukemia and Lymphoma</i> , 1999, 33, 93-99.	1.3	88
375	Neurolymphomatosis in Waldenström's macroglobulinaemia. <i>British Journal of Haematology</i> , 1999, 106, 100-103.	2.5	22
376	Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. <i>British Journal of Haematology</i> , 1999, 104, 723-729.	2.5	114
377	Nodular Glomerulosclerosis with Deposition of Monoclonal Immunoglobulin Heavy Chains Lacking CH1. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 519-528.	6.1	65
378	Use of an Abdominal Compression Device for CT-guided Biopsy of Enlarged Abdominal or Pelvic Lymph Nodes. <i>Journal of Vascular and Interventional Radiology</i> , 1998, 9, 353-357.	0.5	14

#	ARTICLE	IF	CITATIONS
379	Granulocytic sarcoma of the jejunum: a rare cause of small bowel obstruction. American Journal of Gastroenterology, 1998, 93, 2586-2588.	0.4	36
380	Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer, 1995, 76, 1559-1563.	4.1	37
381	Hepatitis C Virus in Saliva. Annals of Internal Medicine, 1995, 122, 556.	3.9	24
382	Iliac artery dissection in α 1-antitrypsin deficiency. Lancet, The, 1994, 343, 1371-1372.	13.7	32
383	Detection of human t lymphotropic virus type itax gene in salivary gland epithelium from two patients with sjögren's syndrome. Arthritis and Rheumatism, 1993, 36, 1423-1428.	6.7	83
384	Nucleotidic sequence analysis of the variable domains of four human monoclonal IgM with an antibody activity to myelin-associated glycoprotein. European Journal of Immunology, 1993, 23, 846-851.	2.9	17
385	Hepatitis C virus and Sjögren's syndrome. Arthritis and Rheumatism, 1993, 36, 280-281.	6.7	78
386	Bone densitometry in patients with multiple myeloma. American Journal of Medicine, 1992, 93, 595-598.	1.5	38
387	Sensorimotor polyneuropathy and monoclonal IgM: A review of clinical and immunological features. International Journal of Clinical and Laboratory Research, 1992, 22, 201-205.	1.0	5
388	Rifampicin-induced pure red cell aplasia. American Journal of Medicine, 1989, 87, 459-460.	1.5	18
389	Monarthritis revealing non-hodgkin's t cell lymphoma of the synovium. Arthritis and Rheumatism, 1988, 31, 571-572.	6.7	23